Ertugliflozin L-Pyroglutamic Acid (CAS 1210344-83-4)

Application and positioning

Ertugliflozin L-pyroglutamic acid is an SGLT2 inhibitor supplied as the L-pyroglutamic acid cocrystal. It is used in oral tablets for glycaemic control in type 2 diabetes, alone or with sitagliptin and metformin. Laurand supplies it from audited Chinese production partners for pharmaceutical manufacturing and process development.

Quality and documentation

• Batch-specific Certificate of Analysis issued by the manufacturing site
• SDS/MSDS and specification sheet available on request
• Residual solvents and elemental impurities statements discussed per project
• For pharmaceutical manufacturing and R&D use only — not for direct administration

Packaging and handling

• Packed in double polyethylene-lined fibre drums; pack size confirmed at quotation
• Small quantities in sealed aluminium foil bags
• Palletised for air and sea freight; store dry, ventilated and protected from light

Related products

• Sotagliflozin (CAS 1018899-04-1)
• Trelagliptin Succinate (CAS 1029877-94-8)
• Alogliptin benzoate (CAS 850649-62-6)
• Dapagliflozin (CAS 461432-26-8)

Specifications shown are indicative. The final specification and documentation package are confirmed with the quotation.